The Third Congress of the Macedonian Haematology Association with International Participation

Location of the meeting: Hotel Double Tree by Hilton - Skopje

Day 1: September 12, 2023 (Tuesday)

11:30-12:30 Registration
12:30-13:15 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "TRISENOX ® (arsenic trioxide) established therapy in the treatment of APL"
13:15-14:00 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "Daruph - Added Value Dasatinib in treatment of Leukemia"
14:00-15:00 Opening ceremony and welcome drink
Session Chair: Dimitar Efremov, Irina Panovska-Stavridis
  Current treatment options for ALL Foa Roberto, Sapienza University, Rome, Italy

GENERAL SESSION 1: How I treat Chronic Lymphocytic Leukemia (CLL)

Session Chairs: Dimitar Efremov, Sanja Trajkova
Time table Title Speaker
15:25-15:50 Time-limited vs continuous treatment options for CLL Vincent Lévy, Hopital Avicenne, APHP, Bobigny, France
15:50-16:15 Remaining challenges in CLL: Resistance to targeted therapies and Richter transformation Dimitar Efremov ICGEB Trieste, Italy

GENERAL SESSION 2: How I treat Non-Hodgkin Lymphomas (NHL)

Session Chairs: Zlate Stojanovski, Gordana Petrusevska
Time table Title Speaker
16:15-16:40 Current treatment options for Waldenstrom Macroglobulinemia Luca Laurenti, IRCCS Agostino Gemelli University Policlinic, Rome, Italy 
16:40-17:05 Current treatment options for Follicular Lymphoma Dr Patten Piers, Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, King’s college London, UK
17:05-17:30 Current treatment options for Diffuse Large B-cell lymphoma Bosch Albareda Francisko, Department of Haematology, University Hospital Vall d’Hebron, Autonomous University, Barcelona, Spain
17:30-17:55 Point of Care CAR-T Cell Development - UMC Ljubljana, Slovenia Experience Sever Matjaz, University Medical Centre Ljubljana, Slovenia
17:55-18:15 Coffee break
18:15-19:00 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "LUNSUMIO changes the patients outcomes in relapse or refractory follicular lymphoma"
19:00 Dinner

Day 2: September 13, 2023 (Wednesday)

09:00-09:45 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "The role of BESPONSA in patients with ALL R/R"
09:45-10:30 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "New horizons in the treatment of Hematologic Malignancies"
10:30-11:15 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "Advances in myelofibrosis and polycythemia vera: jakavi as the current and evolving treatment"
11:15-11:30 Coffee break

GENERAL SESSION 3: How I treat Hodgkin Lymphoma (HL)

Session Chairs: Oliver Karanfilski, Basic Kinda Sandra
Time table Title Speaker
11:30-11:55 Current treatment options for Hodgkin Lymphoma Igor Aurer, KBC Zagreb, Croatia
11:55-12:20 Treatment approach for Hodgkin lymphomas in North Macedonia Oliver Karanfilski , University Clinic of Hematology – Skopje, North Macedonia
12:20-12:45 Updates in the role of check point inhibitors in the treatment of Hodgkin lymphoma Theodoros Vassilakopoulos, National and Kapodistrian University of Athens, Greece

GENERAL SESSION 4: How I treat Multiple Myeloma (MM)

Session Chairs: Svetlana Krstevska-Balkanov, Svetlana Stankovik
Time table Title Speaker
12:45-13:10 Real World Evidence (RWE): standards, recommendations and current clinical practice in diagnostics and treatment of multiple myeloma Jelena Bila, Klinicki Centar Srbije, Belgrade, Serbia
13:10-13:35 Plasma cell dyscrasias excluding Multiple Myeloma Samo Zver, University Medical Centre Ljubljana, Slovenia
13:35-14:00 Treatment of refractory/relapsed Multiple Myeloma Evangelos Terpos, National and Kapodistrian University of Athens, Greece

GENERAL SESSION 1: How I treat Chronic Lymphocytic Leukemia (continued)

Session Chair: Aleksandar Dimovski
  Realizing precision medicine in CLL-where do we stand now? Kostas Stamatopoulos, Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece
14:25-15:00 Lunch
15:00- 16:15

GENERAL SESSION 5:  How I treat Myeloproliferative Neoplasms (MPN)

Session Chairs: Irina Panovska-Stavridis, Marica Pavkovik
Time table Title Speaker
15:00-15:25 Current treatment options for Chronic myeloid leukemia (CML) Giuseppe Saglio, University of Turin, Italy
15:25-15:50 Current treatment options for essential thrombocytosis (ET) or polycythemia vera (PV) Tiziano Barbui, FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
15:50-16:15 Current treatment options for primary myelofibrosis (PMF)  Andrea Bacigalupo, IRCCS Agostino Gemelli University Policlinic,  Rome, Italy

GENERAL SESSION 6: State of art stem cell transplantation

Session Chairs: Aleksandra Pivkova-Veljanovska, Aleksandar Petlickovski
Time table Title Speaker
16:15-16:40 How to prevent relapse in Acute myeloblastic leukemia (AML) after allogeneic transplant Kroeger Nikolaus Martin, University Medical Center Hamburg-Eppendorf, Germany
16:40-17:05 Toxicity, Drug Interactions & Follow-up  in Allogeneic Stem Cell Transplantation Yener Koç, Medicana Hospital, Istanbul, Turkey
17:05-17:30 Chronic Graft Versus Host Disease (GVHD) Zinaida Perić - Rebro, Zagreb
17:30-17:55 The best Immunotherapy for Acute Lymphoblastic Leukaemia Prof. Christina Peters, Children's Cancer Research Institute, Vienna (CCRI)
17:55-18:10 Coffee break
18:10-18:55 PHARMACEUTICAL INDUSTRY SYMPOSIUM : "Proteasome Inhibitors as a Treatment Backbone in Relapse Refractory Multiple Myeloma"
20:30-23:00 GALA DINNER

Day 3: September 14, 2023 (Thursday)

09:00-09:45 PHARMACEUTICAL INDUSTRY SYMPOSIUM 9: Sandoz - "RIXATHON® development and real world evidence data"
09:45-10:30 PHARMACEUTICAL INDUSTRY SYMPOSIUM: "Our challenges and perspectives in DLBCL segment"
10:30-10:45 Coffee break

GENERAL SESSION 7: State of art treatment of cancer associated thrombosis and haematological emergencies

Session Chairs: Martin Ivanovski, Sotirova Tatjana
Time table Title Speaker
10:30-10:55 Cancer associated thrombosis risk and challenges Grigorios Gerotziafas, Centre de Recherche Saint Antoine Paris, France
10:55-11:20 Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment Darko Antic, Klinicki Centar Srbije, Belgrade, Serbia
11:20-11:45 The current treatment recommendations on acquired Thrombotic thrombocytopenic purpura (TTP) Drazen Pulanic, KBC Zagreb, Croatia
11:45-12:00  Coffee break  

GENERAL SESSION 8: Paediatric haematology 

Session Chairs: Kocheva Svetlana, Zorica Antevska
Time table Title Speaker
12:00-12:25  Genetics of childhood acute lymphoblastic leukemia Prof. Haas Oskar Arthur, St Anna's Kinderspital, Vienna
12:25-12:50 Advances in childhood acute lymphoblastic leukemia - experiences and perspectives of the ALLIC trials Prof. Kiss Csongor , University of Debrecen, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology-Oncology"
12:50-13:15 Innovative therapies in childhood AML Ass. Prof. Jelena Lazic Department for hematology and oncology University Children`s Hospital
School of Medicine, University of Belgrade
13:15-14:00 SPONSORED SYMPOSIUM "Treatment of acute lymphoblastic leukemia in childhood"
14:00-14:30 Lunch
14:30-15:30 Poster viewing and oral presentation of the 3 best awarded posters
Session Chairs: Lidija Cevreska, Aleksandar Stojanovik, Borce Georgievski
15:30 Closing of the congress: ADJOURN